Genmab A/S (OTCMKTS:GNMSF - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $190.15 and last traded at $190.15, with a volume of 717 shares traded. The stock had previously closed at $197.44.
Genmab A/S Stock Up 0.7 %
The firm has a market cap of $12.65 billion, a price-to-earnings ratio of 18.40 and a beta of 1.04. The stock's 50-day moving average price is $209.38 and its 200 day moving average price is $233.81.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
